Immunoprotein Diagnostic Testing Industry Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Immunoprotein diagnostic testing encompasses immunoassay techniques, including ELISA, western blotting, immunoturbidity, immunofluorescence, and nephelometry, that detect specific proteins, antibodies, or antigens in patient samples. While sitting within the broader diagnostic testing market valued at approximately $243.25 billion globally, the immunoprotein segment alone was valued at USD 9.60 billion in 2024 and is forecast to reach USD 16.75 billion by 2032. This segment serves as a critical tool across clinical laboratories, hospitals, and point-of-care settings for diagnosing a wide range of conditions.

• •The broader diagnostic testing market reached $243.25 billion in 2025 and is projected to grow to $483.45 billion by 2035
• •The immunoprotein diagnostics sub-segment was valued at $9.60 billion in 2024 and is expected to reach $16.75 billion by 2032
• •Key technologies include ELISA, immunoturbidity assays, western blotting, immunofluorescence, and nephelometry

The primary forces propelling market expansion include the global rise in chronic and infectious diseases, coupled with an aging demographic that requires more frequent diagnostic monitoring. Technological advancements in immunoassay sensitivity, automation, and point-of-care testing platforms have made immunoprotein diagnostics faster, more accurate, and more accessible. The COVID-19 pandemic accelerated investment in diagnostic infrastructure, regulatory pathways, and laboratory capacity that continues to benefit the broader immunodiagnostics sector.

• •Rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer increases demand for protein-based diagnostic tests
• •Advancements in immunoassay technology, including chemiluminescent immunoassays and multiplex testing, improve accuracy and throughput
• •Aging populations globally drive higher diagnostic testing volumes and more frequent monitoring requirements

The immunoprotein diagnostics market is segmented by technology type, application area, end user, and geography. Infectious disease testing constitutes the largest application segment, followed by oncology, cardiology, autoimmune disorders, and allergy testing. Geographically, North America leads the market due to advanced healthcare infrastructure and high diagnostic adoption rates, while the Asia-Pacific region is the fastest-growing market driven by rising healthcare access, increasing disease burden, and growing laboratory capacity.

• •Infectious disease diagnostics remains the dominant application segment within immunoprotein testing
• •North America holds the largest market share, while Asia-Pacific is the fastest-growing region
• •Key end users include hospitals and clinics, independent diagnostic laboratories, and increasingly, home-care and point-of-care settings

What are the recent trends and outlook?

The market is moving toward greater integration of immunoassay platforms with laboratory information systems, enabling streamlined workflow automation and improved data management. Point-of-care immunoprotein testing is gaining traction, driven by demand for rapid results in decentralized settings such as physician offices and urgent care centers. Looking ahead, the convergence of immunoassay technology with molecular diagnostics and artificial intelligence-based result interpretation is expected to create new growth opportunities and further expand the addressable market through 2032 and beyond.

• •Point-of-care immunoprotein testing is expanding as demand grows for rapid, decentralized diagnostics outside traditional laboratory settings
• •Integration with digital health platforms and laboratory information management systems is improving workflow efficiency
• •Emerging economies in Asia-Pacific, Latin America, and the Middle East represent significant untapped growth opportunities as healthcare infrastructure expands